RESEARCH SPOTLIGHT

A new study using next-generation sequencing finds that more than 1 in 5 appendix cancer samples carry mutations that could be matched to existing or emerging drugs. The catch: it depends on the subtype, and most patients still aren’t getting tested.

If you or someone you love has been diagnosed with appendix cancer, you’ve probably heard the same phrase more than once. There’s no standard treatment. The drugs we use come from colon cancer. We treat what’s in front of us.

That’s the honest truth of where the field has been. But research published in May 2026 in the Annals of Surgical Oncology adds a piece of evidence that matters for patients sitting in oncology offices right now. A team at Wake Forest Baptist analyzed 916 appendiceal tumor samples from 17 institutions through the AACR Project GENIE database. They sorted them by subtype. Then they asked a simple question. How many of these tumors carry mutations that an existing or emerging drug could target?

The answer was more than 1 in 5.

More than one in five appendiceal samples carried mutations with drug-targeting potential. Each subtype had its own mutation profile.

What the study actually did

The researchers looked at five appendiceal subtypes that should be familiar to anyone in our community. Appendiceal adenocarcinoma not otherwise specified, mucinous adenocarcinoma, goblet cell adenocarcinoma, signet ring cell adenocarcinoma, and LAMN. They ran the genetic data through next-generation sequencing to find out which genes were mutated in each subtype.

Then they cross-referenced those mutations against databases of cancer drugs that target specific genetic changes. Some of these drugs are already FDA approved for other cancers. Some are still in clinical trials. The team wanted to know which appendix cancer patients, in theory, could be candidates for that kind of treatment if their tumors were tested.

Two findings stand out. The five subtypes had distinct mutation profiles, which means they are genetically different diseases that happen to live in the same organ. And across the full group, more than 20 percent of samples carried a mutation with drug-targeting potential.

Next-generation sequencing, in plain English

Next-generation sequencing, usually shortened to NGS, is a way of reading the DNA of a tumor. The lab takes a piece of tumor tissue, or sometimes a blood draw, and runs it through machines that can check hundreds of cancer-related genes at once. The result is a report that lists which genes in your tumor are mutated or changed.

This matters because some mutations are clues. If a tumor carries a mutation in a specific gene, and there is a drug that blocks the protein that gene makes, the drug may shrink the tumor or slow it down. This is what people mean by targeted therapy. It is not chemotherapy in the traditional sense. It is medicine matched to a specific genetic change.

In common cancers like lung and breast, NGS is now routine. In appendix cancer, it is not. Patients often have to ask for it directly. Some are told it won’t change their treatment, which is sometimes true and sometimes not. This study is one of the larger arguments for testing more patients, more often.

PLAIN-LANGUAGE GLOSSARY Mutation. A change in a gene. Some mutations help cancer grow. A few of those can be blocked with the right drug. Targeted therapy. A drug designed to block a specific protein that a mutated gene makes. Different from chemotherapy, which kills fast-dividing cells more broadly. Actionable mutation. A mutation that has an FDA-approved drug, an off-label option, or an open clinical trial matched to it. AACR Project GENIE. A shared cancer genetics database run by the American Association for Cancer Research that pools tumor sequencing data from cancer centers around the world.

Why the subtype finding matters most

The headline 1-in-5 number is encouraging, but the more useful detail is buried underneath it. Each subtype had its own mutation pattern. That confirms what patients and clinicians who work in this space have been saying for years. Appendix cancer is not one disease. Goblet cell adenocarcinoma is biologically different from LAMN. Signet ring cell is different from mucinous adenocarcinoma. Treating them as interchangeable, the way some treatment guidelines still effectively do, leaves real options on the table.

The Wake Forest team did not publish a treatment guide. They did not tell oncologists which drug to use for which mutation. The study’s job was to show the genetic terrain, not to draw the map. But the terrain itself argues for two things. Sequencing should be considered for patients across appendiceal subtypes, not just one or two. And when a mutation does show up that has a known drug match, it deserves a real conversation between patient and oncologist, not a dismissal.

What this study does not say

It does not say that targeted therapy works in appendix cancer. It says that targets exist. Whether a drug that shrinks lung tumors with a particular mutation will do the same to an appendix tumor with the same mutation is a separate question that requires clinical trials. Some early evidence in appendix cancer is promising. Some is mixed. None of it is settled.

It also does not say that every patient should be sequenced. NGS testing costs money, is not always covered by insurance, and the report can sit in a file unused if no one on the care team knows what to do with it. For patients with stable, low-grade disease and a clear surgical plan, the test may not change anything in the short term.

What the study does suggest, strongly, is that the field has been treating appendix cancer with less genetic information than it could be using. For patients with high-grade disease, recurrent disease, or limited options, that gap has consequences.

Appendix cancer is not one disease. The genetic profile of a goblet cell tumor is not the genetic profile of a LAMN. Treatment plans should reflect that.

What patients can actually do with this

If you have not already had your tumor tested with NGS, ask whether it is an option. Tissue from your original surgery or biopsy can often be used, even years later. Some patients use tissue-based panels through their hospital. Others use commercial panels like FoundationOne CDx, Tempus xT, or Caris Molecular Intelligence. If tissue is not available or is too old, liquid biopsy through a blood draw is sometimes an alternative, though it tends to miss more in appendix cancer than in other tumor types.

If you have already had testing done, find the report and bring it to your oncology appointment. Ask what mutations were found, whether any are considered actionable, and whether there are clinical trials that match your specific profile. A second opinion from a high-volume appendix cancer center, especially for goblet cell, signet ring cell, or high-grade disease, can surface options a general oncologist may not know about.

QUESTIONS TO ASK YOUR ONCOLOGIST › Has my tumor been tested with next-generation sequencing? If not, is it an option for me now? › Which specific genes were tested, and which mutations did the report identify? › Are any of my mutations considered actionable, meaning there is a drug or clinical trial that targets them? › Does my subtype change which mutations matter most? For example, are there findings specific to goblet cell, signet ring, or mucinous adenocarcinoma? › If a mutation is actionable but the drug is approved for another cancer, is off-label use or a clinical trial worth discussing? › Would a second opinion at a high-volume appendix cancer center change anything about my treatment plan?

The bigger picture

Studies like this one move appendix cancer closer to where common cancers have been for a decade. The technology to read the genetic signature of a rare tumor is here. The databases that compare your tumor against thousands of others are here. The drugs that target specific mutations are growing every year. What is still catching up is the assumption, baked into too many treatment conversations, that there is nothing more to look for.

There is more to look for. For 1 in 5 patients in this study, what was found could matter.

SHARE THIS New study: 916 appendix cancer tumors, 5 subtypes, distinct genetic profiles, and drug-targeting mutations in more than 1 in 5 samples. Next-generation sequencing should be on the table for more appendix cancer patients. Ask your oncologist.

SOURCE

Zheng-Pywell R, Lumia SJ, Cos Felipe H, Gironda DJ, Miller LD, Levine EA. Next-Generation Sequencing Identifies Key Targetable Mutations in the Treatment of Appendiceal Neoplasms. Annals of Surgical Oncology. Published online May 8, 2026. Wake Forest University Comprehensive Cancer Center, with data drawn from the AACR Project GENIE registry across 17 institutions.

Springer Nature Link: ASO Visual Abstract: Next-Generation Sequencing Identifies Key Targetable Mutations in the Treatment of Appendiceal Neoplasms

Note: This article summarizes published research for patient education. It is not medical advice. Treatment decisions should be made with your oncology team.